Integra Lifesciences Holdings Corp (NASDAQ:IART) 2017 Q3 Sentiment Report

January 19, 2018 - By Winifred Garcia

 Integra Lifesciences Holdings Corp (NASDAQ:IART)  2017 Q3 Sentiment Report

Sentiment for Integra Lifesciences Holdings Corp (NASDAQ:IART)

Integra Lifesciences Holdings Corp (NASDAQ:IART) institutional sentiment increased to 1.29 in 2017 Q3. Its up 0.15, from 1.14 in 2017Q2. The ratio is positive, as 106 institutional investors increased and opened new positions, while 82 sold and reduced their stakes in Integra Lifesciences Holdings Corp. The institutional investors in our partner’s database now possess: 68.21 million shares, up from 66.26 million shares in 2017Q2. Also, the number of institutional investors holding Integra Lifesciences Holdings Corp in their top 10 positions decreased from 3 to 2 for a decrease of 1. Sold All: 22 Reduced: 60 Increased: 80 New Position: 26.

Integra LifeSciences Holdings Corporation develops, makes, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company has market cap of $3.94 billion. The firm operates through two divisions, Specialty Surgical Solutions; and Orthopedics and Tissue Technologies. It has a 82.13 P/E ratio. It offers neurosurgery and critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment.

The stock increased 0.38% or $0.19 during the last trading session, reaching $50.18. About 522,475 shares traded. Integra LifeSciences Holdings Corporation (NASDAQ:IART) has risen 32.67% since January 19, 2017 and is uptrending. It has outperformed by 15.97% the S&P500.

Analysts await Integra LifeSciences Holdings Corporation (NASDAQ:IART) to report earnings on February, 22. They expect $0.56 earnings per share, up 7.69 % or $0.04 from last year’s $0.52 per share. IART’s profit will be $43.95M for 22.40 P/E if the $0.56 EPS becomes a reality. After $0.45 actual earnings per share reported by Integra LifeSciences Holdings Corporation for the previous quarter, Wall Street now forecasts 24.44 % EPS growth.

Sector Gamma As holds 4.07% of its portfolio in Integra LifeSciences Holdings Corporation for 529,230 shares. Champlain Investment Partners Llc owns 4.54 million shares or 2.7% of their US portfolio. Moreover, Falcon Point Capital Llc has 1.73% invested in the company for 255,207 shares. The Colorado-based Tributary Capital Management Llc has invested 1.61% in the stock. Pier Capital Llc, a Connecticut-based fund reported 112,576 shares.#img1#

Integra LifeSciences Holdings Corporation (NASDAQ:IART) Ratings Coverage

Ratings analysis reveals 53% of Integra Lifesciences Holdings Corp.’s analysts are positive. Out of 15 Wall Street analysts rating Integra Lifesciences Holdings Corp., 8 give it “Buy”, 0 “Sell” rating, while 7 recommend “Hold”. The lowest target is $44.0 while the high is $96. The stock’s average target of $60.73 is 21.02% above today’s ($50.18) share price. IART was included in 35 notes of analysts from July 29, 2015. RBC Capital Markets maintained the stock with “Hold” rating in Monday, October 2 report. The firm has “Hold” rating by Zacks given on Monday, August 24. The firm has “Buy” rating given on Friday, June 23 by Oppenheimer. The stock has “Buy” rating by Piper Jaffray on Monday, September 11. As per Friday, October 27, the company rating was downgraded by JP Morgan. On Wednesday, August 26 the stock rating was maintained by Lake Street with “Hold”. The firm has “Buy” rating given on Friday, September 8 by Jefferies. Barclays Capital maintained it with “Equalweight” rating and $77 target in Thursday, June 2 report. As per Friday, October 28, the company rating was upgraded by Lake Street. JP Morgan initiated Integra LifeSciences Holdings Corporation (NASDAQ:IART) on Wednesday, July 13 with “Overweight” rating.

More notable recent Integra LifeSciences Holdings Corporation (NASDAQ:IART) news were published by: Globenewswire.com which released: “Integra LifeSciences Announces Definitive Agreement to Sell Certain …” on September 11, 2017, also Globenewswire.com with their article: “Integra LifeSciences Launches Integra® SurgiMendâ„¢ PRS Meshed Collagen Matrix …” published on October 03, 2017, Seekingalpha.com published: “5 Favorites In Life Sciences: Integra, Emergent, Tekla, Utah Medical, And Veeva” on January 18, 2018. More interesting news about Integra LifeSciences Holdings Corporation (NASDAQ:IART) were released by: Globenewswire.com and their article: “Integra LifeSciences launches Revizeâ„¢/ Revizeâ„¢-X Collagen Matrix for Plastic …” published on October 06, 2017 as well as Seekingalpha.com‘s news article titled: “Integra LifeSciences Holdings’ (IART) CEO Peter Arduini on Q3 2017 Results …” with publication date: October 26, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: